Acción ONCOLOGY VENTURE A/S
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Oncology Venture A/S Nasdaq Stockholm

Acciones

Precio de cierre Nasdaq Stockholm
Otros sitios de cotización
- SEK - Gráfico intradía de Oncology Venture A/S
24/05 Allarity Therapeutics, Inc. concluye su ensayo clínico de fase 2 CI
02/05 Wall Street abrirá al alza el jueves después de que la Fed mantuviera los tipos sin cambios y de que las peticiones de subsidio de desempleo fueran inferiores a lo esperado MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Top Premarket Gainers
Top Premarket Gainers
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
Allarity Therapeutics : Material Agreement - Form 8-K
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ALLR
  4. Acción
  5. Noticias Oncology Venture A/S
  6. Otros idiomas